Filing Details
- Accession Number:
- 0000899243-22-009062
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-03-03 16:15:41
- Reporting Period:
- 2022-03-01
- Accepted Time:
- 2022-03-03 16:15:41
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1466301 | Clovis Oncology Inc. | CLVS | Pharmaceutical Preparations (2834) | 900475355 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1650504 | Lindsey Rolfe | C/O Clovis Oncology, Inc. 5500 Flatiron Parkway, Suite 100 Boulder CO 80301 | See Remarks | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-03-01 | 688 | $0.00 | 87,177 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-03-02 | 360 | $1.87 | 86,817 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2022-03-01 | 20,250 | $0.00 | 107,067 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-03-02 | 10,585 | $1.87 | 96,482 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Units | Acquisiton | 2022-03-01 | 81,000 | $0.00 | 81,000 | $0.00 |
| Common Stock | Restricted Stock Units | Acquisiton | 2022-03-01 | 20,250 | $0.00 | 20,250 | $0.00 |
| Common Stock | Restricted Stock Units | Acquisiton | 2022-03-01 | 688 | $0.00 | 688 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 81,000 | No | 4 | A | Direct | ||
| 60,750 | No | 4 | M | Direct | ||
| 0 | No | 4 | M | Direct |
Footnotes
- Each Restricted Stock Unit represents the right to receive one share of Common Stock.
- Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
- This transaction was executed in multiple trades at prices ranging from $1.862 to $1.866. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- The Restricted Stock Units shall vest as to 25% of the units on March 1, 2023, and the remainder shall vest in substantially equal installments over the 12 quarters immediately following such date.
- On March 1, 2021, the reporting person was granted 81,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2022, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date
- On March 1, 2018 , the reporting person was granted 11,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
Billionaire Hedge Funds
